Evolution in the life science industry, especially as a solution provider, can no longer be just an advertising slogan, it is an operational necessity. The complexity of clinical trial designs is increasing rapidly, as are data volumes with biomarker and real-world data being utilized in scope of clinical trials. At the same time, regulatory authorities are striving towards more transparency and agility in the submission process while supporting an increasing amount of data formats and technologies for submission artifacts. Our rebranding and website redesign at entimo is not just about a new look, it is an expression of how we are shaping our evolution.

entimo’s 2025 Climate Change rating from CDP (formerly the Carbon Disclosure Project) has improved significantly compared to 2024, and now stands at a B level. This marks meaningful progress in our environmental transparency and climate action efforts. A rating at this level recognizes verified, evidence-based climate action and shows that entimo has moved from awareness into meaningful implementation.

The 33rd BVMA Symposium in Munich brought together an extraordinary cross-section of Germany’s clinical research landscape including industry leaders, regulatory agencies, CROs, sponsors, NGOs, and government representatives. For entimo’s CEO, Marc Jantke, it was his first time stepping into what some attendees call a “class reunion.” As it turned out, the nickname was more accurate than he expected.